Clinical trials: Neoplasms, Hematopoietic
Acute Myeloid Leukemia, Precursor-cell Lymphoblastic Leukemia-Lymphoma
Prevention of Left Ventricular Dysfunction During Chemotherapy
The investigators' objective is to assess the efficacy of the combined treatment with enalapril and carvedilol in the prevention of left ventricular systolic dysfunction in patients with hematological malignancies submitted to…
- Conditions
- Acute Myeloid Leukemia, Precursor-cell Lymphoblastic Leukemia-Lymphoma, Lymphoid Neoplasm, Multiple Myeloma
- Trial name
- OVERCOME (NCT01110824)
- Testing
- Enalapril and carvedilol
- Where
- 2 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hospital Clinic of Barcelona
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of bortezomib when given together with fludarabine with or without rituximab in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma or…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT00068315
- Testing
- bortezomib, fludarabine phosphate, rituximab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Cachexia, Gastrointestinal Cancer
Screening to Predict Weight Loss in Patients With Cancer
RATIONALE: Screening tests may identify people with cancer who are at high risk of losing weight and help doctors plan better treatment.
- Conditions
- Cachexia, Gastrointestinal Cancer, Hematopoietic/Lymphoid Cancer, Lung Cancer
- Trial name
- NCT00710632
- Testing
- laboratory biomarker analysis, physiologic testing, questionnaire administration
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Queen's Medical Center
Hematopoietic/Lymphoid Cancer
Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of abnormal cells.
- Trial name
- NCT00959231
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- 6 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of decitabine in treating patients with metastatic or unresectable refractory solid tumors or lymphomas.
- Trial name
- NCT00089089
- Testing
- decitabine, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic/Lymphoid Cancer, Pain
Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain
RATIONALE: Opioids lessen pain caused by cancer. It is not yet known whether opioids are more effective when given together with or without olanzapine in treating cancer pain.
- Conditions
- Hematopoietic/Lymphoid Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00737191
- Testing
- olanzapine
- Sponsor
- Mayo Clinic
Hematological Neoplasms, Hematopoietic Stem Cell Transplantation
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
- Trial name
- NCT00582894
- Testing
- Busulfex, Fludarabine, ALemtuzumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Oklahoma
Kaposi's Sarcoma AIDS Related, Kaposi's Sarcoma Classical
AIDS and Cancer Specimen Bank (ACSB)
The purpose of this study is to obtain clinical specimens from pathologists and physicians involved in the diagnosis and care of patients with AIDS and non-AIDS associated malignancies.
- Conditions
- Kaposi's Sarcoma AIDS Related, Kaposi's Sarcoma Classical, Non-Hodgkin's Lymphoma, HEMATOPOIETIC SYSTEM
- Trial name
- NCT00587912
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, Hematopoietic Stem Cell Transplantation
Spouses/Partners Expressing Their Thoughts After Transplant
This study seeks to test a brief psychological intervention for spousal caregivers of cancer patients (specifically, hematopoietic stem cell transplant patients), persons known to experience emotional distress.
- Trial name
- NCT01061801
- Testing
- Emotional expression
- Where
- United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Hematopoietic Stem Cell Transplantation
Ambulatory Physical Exercise Program in Hematopoietic Stem Cell Transplantation Recipients
The proposed study in an inception cohort of patients with hematological malignancies treated with PBSCT is designed to evaluate the effects of a physical exercise intervention on muscular-skeletal, physical activity and quality…
- Trial name
- NCT00402753
- Testing
- Ambulatory Physical Exercise Program
- Where
- 4 sites in Netherlands, Switzerland
- Volunteers
- 128 people
- Sponsor
- University of Zurich
Sepsis, Hematologic Neoplasms
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
The purpose is to determine how Drotrecogin Alfa (activated) will affect patients with blood cancers who develop severe sepsis within 60 days of starting chemotherapy in preparation for bone marrow transplant (BMT).
- Conditions
- Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection
- Trial name
- NCT00067730
- Testing
- Drotrecogin Alfa (activated)
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company